On April 30, 2020 Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, reported it will host a conference call on Thursday, May 7, 2020 at 8:00am ET to discuss recent business updates (Press release, Magenta Therapeutics, APR 30, 2020, View Source [SID1234556825]). The call will also feature a discussion of current stem cell transplant practices by a transplant key opinion leader.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
To access the call, please reference the dial-in details below. A playback of the call will be available on the Magenta Therapeutics website at View Source for 90 days following the call.
Conference ID number: 9594495
U.S./CANADA: (866) 688-5232; (409) 217-8328
UK (London): 08000288438
Switzerland: 0225803283
Australia: 1800005989